Previous close | 13.38 |
Open | 13.32 |
Bid | 0.00 x 4000 |
Ask | 13.26 x 1200 |
Day's range | 13.21 - 13.33 |
52-week range | 13.11 - 17.11 |
Volume | |
Avg. volume | 1,828,361 |
Market cap | 41.919B |
Beta (5Y monthly) | 0.54 |
PE ratio (TTM) | 36.75 |
EPS (TTM) | 0.36 |
Earnings date | N/A |
Forward dividend & yield | 0.64 (4.82%) |
Ex-dividend date | 28 Sept 2023 |
1y target est | 18.24 |
CIB, TAK and ASBFY made it to the Zacks Rank #1 (Strong Buy) income stocks list on April 25, 2024.
A closer look at one of the leaders in the global Crohn's disease treatment market
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced positive topline data for its Phase 2 SAVITRI™ study. This randomized, double-blind, placebo-controlled dose-finding study assessed the efficacy and safety of NBI-1065845 in adult subjects with major depressive disorder (MDD). NBI-1065845 is an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) positive allosteric modulator (PAM) in development as a potential treatment for patients with MDD who have not be